Dr. Daniel Kim is the Director of Genitourinary Radiation Oncology, Chief of Prostate Brachytherapy and Co-Director of the Radiosurgery Program at Inova Schar Cancer Institute. Dr. Kim graduated top of his class at Amherst College with degrees in neuroscience and music while becoming a four-time All-American tennis athlete and winning the NCAA Men’s Tennis Championship, the first title in men’s tennis team history. He graduated with his M.D. and M.B.A., with honors, from Harvard Medical School and Harvard Business School, respectively. He was awarded the Michael E. Porter Leadership Award upon graduation and was invited to serve as a cabinet-level Senior Advisor to then-Mayor Marty Walsh, shaping economic and healthcare policy for the city of Boston and Commonwealth of Massachusetts. Dr. Kim completed his internal medicine internship at Harvard Medical School’s Brigham and Women’s Hospital where he was recognized for his clinical excellence. He completed his residency at the Harvard Radiation Oncology Program which included training at Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women’s Hospital, and Boston Children’s Hospital. He was elected Chief Resident by the Harvard Medical School faculty and his peers in residency at the Harvard hospitals, where he successfully developed clinical and educational directives for the largest radiation oncology residency in the country across all the major Harvard teaching hospitals.

Dr. Kim is board certified in radiation oncology and trained in all aspects of radiation oncology with experience in advanced radiation therapy modalities including proton radiotherapy, stereotactic radiosurgery (SRS), stereotactic ablative radiotherapy (SBRT/SABR), intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), MRI-linear accelerator radiotherapy, adaptive radiotherapy, high-dose rate (HDR) brachytherapy, low-dose rate (LDR) brachytherapy, intraoperative radiotherapy (IORT), and radioligand/radiopharmaceutical therapy.

He treats patients with all types of cancers and his clinical interests include providing high-level multidisciplinary treatment for genitourinary cancers (prostate, bladder, testicular, kidney, penile, and other urologic cancers), brain and spine tumors (including benign entities such as trigeminal neuralgia and arteriovenous malformations), and gastrointestinal cancers. He is a national expert in the management of prostate cancer who is one of the few physicians that personally offers all modalities for both localized and metastatic prostate cancer treatment in his practice – proton radiotherapy, HDR brachytherapy, LDR brachytherapy, SBRT/SABR on the CyberKnife and linear accelerator, IMRT/VMAT, MRI-guided radiotherapy, radioisotope/radiopharmaceutical therapy, spacer gel placement, and fiducial marker placement. He also has expertise in re-irradiation and metastasis-directed radiotherapy including complex spine SBRT/SABR. He built one of the only radiopharmaceutical programs that is dedicated within radiation oncology nationally that allows for the delivery of radioligands such as Pluvicto. Dr. Kim is also one of a few physicians with extensive knowledge and training in proton SBRT/SABR for various tumor types throughout the body as well as proton SRS and brachytherapy for brain tumors.

Dr. Kim’s academic interests have been in translational science through developing novel biomarkers by analysis of annotated datasets and preclinical studies that inform clinical trial design, particularly those involving radiopharmaceutical therapy. He also has research interests in improving tumor control probability while decreasing normal tissue effects using advanced radiotherapy techniques with proton radiotherapy and brachytherapy. He is widely published and has authored over 50 peer-reviewed research manuscripts in journals such as the New England Journal of Medicine (NEJM), Journal of the American Medical Association (JAMA), Journal of Clinical Oncology (JCO), and Clinical Cancer Research. Dr. Kim is senior editor and author of the 1st edition textbook Translational Radiation Oncology (ISBN: 9780323884235) and written several book chapters.

He has developed and activated multiple phase I and II clinical trials both as investigator-initiated trials and with industry support. Dr. Kim has received grant funding through the National Institutes of Health (NIH), American Association for Cancer Research (AACR), and Department of Defense. He is the principal or co-principal investigator on institutional and national trials. He serves on the NRG Oncology Genitourinary Committee and SWOG Theranostics Committee. He is regularly invited to give lectures on the rapidly evolving management of prostate cancer and personalization of brain tumor therapy as well as presenting his award-winning research at national and international meetings, including AACR, American Society of Clinical Oncology (ASCO), and American Society for Radiation Oncology (ASTRO), Radiosurgery Society (RSS), Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the American Brachytherapy Society (ABS). Dr. Kim serves as an invited reviewer for several major journals including NEJM, JAMA, JCO, Cancer, International Journal of Radiation Oncology – Biology – Physics, European Urology, and Neuro-Oncology. Dr. Kim continues to be actively involved in teaching medical students and residents through clinical training and research. He has appointments as an Assistant Professor at the University of Virginia, an Adjunct Professor at the University of Wisconsin-La Crosse, and a secondary appointment as research faculty at his alma mater Harvard Medical School. He is an active member of the ASCO, ASTRO, AACR, RRS, SNMMI, and ABS.

Outside of the clinic, Dr. Kim enjoys playing sports, skiing, and spending time with his wife and children.